0009 000999 1 month ago | Other | ¥0.32 Per Share |
0009 000999 7 months ago | Other | ¥0.77 Per Share |
0009 000999 14 Jun 2024 | Other | ¥1.15 Per Share |
0009 000999 15 Jun 2023 | Other | ¥0.59 Per Share |
0009 000999 12 Aug 2022 | Other | ¥0.5 Per Share |
13 Mar 2025 Date | | 0.32 Cons. EPS | 0.31 EPS |
25 Oct 2024 Date | | 0.6 Cons. EPS | 0.45 EPS |
24 Aug 2024 Date | | - Cons. EPS | 0.81 EPS |
31 May 2024 Date | | 0.84 Cons. EPS | 1.39 EPS |
15 May 2024 Date | | 0.84 Cons. EPS | 1.39 EPS |
0009 000999 1 month ago | Other | ¥0.32 Per Share |
0009 000999 7 months ago | Other | ¥0.77 Per Share |
0009 000999 14 Jun 2024 | Other | ¥1.15 Per Share |
0009 000999 15 Jun 2023 | Other | ¥0.59 Per Share |
0009 000999 12 Aug 2022 | Other | ¥0.5 Per Share |
13 Mar 2025 Date | | 0.32 Cons. EPS | 0.31 EPS |
25 Oct 2024 Date | | 0.6 Cons. EPS | 0.45 EPS |
24 Aug 2024 Date | | - Cons. EPS | 0.81 EPS |
31 May 2024 Date | | 0.84 Cons. EPS | 1.39 EPS |
15 May 2024 Date | | 0.84 Cons. EPS | 1.39 EPS |
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Wen Duo Wu CEO | XSHE Exchange | CNE0000011K8 ISIN |
CN Country | 20,031 Employees | - Last Dividend | 6 Jun 2025 Last Split | 11 Nov 1999 IPO Date |
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., founded in 1999 and headquartered in Shenzhen, China, is a prominent player in the pharmaceutical industry. Initially known as Sanjiu Pharmaceutical Co., Ltd., the company underwent a name change in February 2010 to better reflect its broadened scope and capabilities in healthcare. Operating both within the People's Republic of China and internationally, the company dedicates itself to the research and development, production, and sale of a wide range of pharmaceutical products. With a focus on innovation and delivering high-quality health solutions, China Resources Sanjiu has established itself as a key provider in the pharmaceutical sector.
In addition to its diverse product lineup, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. also engages in providing related health services. This expansion reinforces its commitment to not only addressing specific health conditions through pharmaceuticals but also enhancing overall healthcare delivery and accessibility.